Zymeworks Announces the Formation of its Therapeutics Advisory Team, and Appointment of VP, Preclinical R&D to Advance its Strategic Therapeutics Initiative

Published: Jan 05, 2012

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a privately held biotherapeutics company focused on the development of best-in-class antibody and next generation protein-based therapeutics, today announced the formation of its therapeutics advisory team and the appointment of a new Vice-President, Preclinical Research and Development.

Back to news